You just read:

Landmark Outcomes Study Shows That Repatha® (Evolocumab) Decreases LDL-C To Unprecedented Low Levels And Reduces Risk Of Cardiovascular Events With No New Safety Issues

News provided by

Amgen

Mar 17, 2017, 09:00 ET